Goal:
13 - İklim Eylemi

Project Logo
Description
İklim Eylemi İklim değişikliği ve etkileri ile mücadele için acilen eyleme geçmek. Dünya üzerinde iklim değişikliğinin ağır etkilerini bizzat yaşamayan tek ülke yoktur. Sera gazı emisyonları atmaya devam ediyor ve şu anda, 1990 yılındaki düzeye göre %50 artmış durumdadır. Doğu Avrupa ve Orta Asya, büyük sera gazı emisyonu üreticileri değiller; ancak iklim değişikliğinin sonuçlarından orantısız biçimde zarar görüyorlar. Küresel ısınma, insanların hayatını ciddi ölçüde etkiliyor. Hemen şimdi harekete geçmeliyiz.

Filters

20132
Reset filters

Settings

End date: 2013 × Start date: 2013 × Type: Article ×

Publication Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience
    (2013-10-01) CEYLAN, Bahadir; CALICA, Aylin; AK, Oznur; Akkoyunlu, YASEMİN; TURHAN, Vedat; AKKOYUNLU, YASEMİN
    Crimean–Congo hemorrhagic fever (CCHF) is a viral infection associated with a high mortality rate. Ribavirin is the only drug used in the treatment of this disease. Studies investigating the effectiveness of ribavirin in CCHF have been retrospective and to date have included only a small number of cases. In recent years, due to climate changes, the number of cases of CCHF in Turkey has increased, and experience in the treatment of CCHF has improved. Several studies have evaluated the efficacy of ribavirin in Turkey, including one randomized controlled trial and two studies with a large number of cases. In these studies, ribavirin therapy was not shown to decrease mortality rates; the mortality rate was 2–9% in patients treated with ribavirin and 5.6–11% in those who were not treated with this drug. These findings suggest that patients with CCHF should be followed with supportive care only until randomized controlled trials with larger groups have been conducted.
  • No Thumbnail Available
    PublicationMetadata only
    Impact of Altitude on Predicting Midterm Outcome in Patients With ST Elevation Myocardial Infarction
    (2013-07-01T00:00:00Z) Isik, Turgay; Tanboga, Ibrahim Halil; Ayhan, Erkan; Uyarel, Huseyin; Kaya, Ahmet; Kurt, Mustafa; Erdogan, Ercan; Ergelen, Mehmet; Cicek, Gokhan; Akgul, Ozgur; Ghannadian, Bahman; KAYA, AHMET
    This study investigated the effects of altitude on occurrence of mid-term negative events among patients presenting with ST elevation myocardial infarction (STEMI). This study enrolled 492 patients with STEMI. 119 of those patients were living at an intermediate altitude (1960 m, Group I) and 373 were living at sea level (0 m, Group II). There was no significant difference between the different altitude groups in terms of the incidence of cardiac death, urgent target vessel revascularization (TVR), stroke/transient ischemic attack (TIA) and composite endpoints. However, Group I had a significantly higher reinfarction incidence when compared with the Group II. Independent predictors of 6-month composite endpoints were history of statin use, presentation with acute stent thrombosis, peak CK-MB level, success of procedure, Killip classification, and left ventricular ejection fraction. In conclusion, altitude status and altitude-related hematologic changes had no influence over the mid-term outcomes in STEMI patients treated with percutaneous intervention.